Sentinel Lymph Node Biopsy in Post-Neoadjuvant Chemotherapy Breast Cancer Patients Using a Combination of Fluorescein and Blue Dye Versus Blue Dye Alone: Randomized Pilot Feasibility Trial.
Rajendar Byshetty B, Vishnoi Jeewan Ram JR, Sharma Nivedita N, Poonia Dharma Ram DR et al.
Sentinel lymph node biopsy is standard for staging clinically node-negative (cN0) breast cancer, but the dual tracer gold-standard radioisotope-blue dye technique is unavailable in resource-limited settings. Fluorescein, an inexpensive, safe, visible-light tracer, has no randomized data after neoadjuvant chemotherapy (NACT). We compared fluorescein-methylene blue with methylene blue alone for sentinel lymph node biopsy in post-NACT cN0 patients and, secondarily, assessed the accuracy of axillary ultrasound. In this randomized pilot feasibility trial, post-NACT cN0 breast cancer patients were randomized 1:1 to fluorescein-methylene blue (FlaB) or methylene blue alone after dye allergy testing. All patients underwent completion axillary lymph node dissection as the reference standard. Identification rate and false-negative rate were estimated with 95% confidence intervals. Of 136 patients who received NACT, 62 (45.6%) had a clinical complete nodal response and were recruited; 2 (3.2%) were excluded for methylene blue allergy, leaving 30 randomized per group, with all 60 completing the protocol. IR: 93.3% (28/30; 95% CI, 78.7-98.1) with FlaB versus 83.3% (25/30; 95% CI, 66.4-92.7) with methylene blue alone (difference, 10.0 percentage points; p = 0.23). FNR: 11.1% (2/18; 95% CI, 3.1-32.8) versus 12.5% (2/16; 95% CI, 3.5-36.0; p = 0.87). On secondary analysis, axillary ultrasound was normal in 30 of 62 patients (48.4%) and suspicious in 32 (51.6%); against final pathology, its sensitivity was 80.6%, and its negative predictive value was 76.7%; 7 of the 36 node-positive patients (19.4%) had a sonographically normal axilla. No dye-related adverse events occurred. FlaB achieved an identification rate above the 90% benchmark and a false-negative rate comparable to radioisotope-based dual-tracer series. Axillary ultrasound did not reliably exclude residual nodal disease (negative predictive value 76.7%) and cannot replace pathological nodal staging after NACT. Fluorescein-methylene blue is a safe, radioisotope-free dual-tracer strategy for SLNB in resource-limited settings.